(Q38003399)

26 August 2017

title

Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection (English)

1 reference

26 August 2017

Jamie D Croxtall

1

1 reference

26 August 2017

language of work or name

1 reference

1 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

72

1 reference

26 August 2017

issue

6

1 reference

26 August 2017

page(s)

847-869

1 reference

Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Transmission of drug-resistant HIV-1 in Europe remains limited to single classes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

The prevalence of antiretroviral drug resistance in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 V

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Local mutagenesis: a method for generating viral mutants with base substitutions in preselected regions of the viral genome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Effects of different meal compositions and fasted state on the oral bioavailability of etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Clinical pharmacokinetics and pharmacodynamics of etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Pharmacokinetic interactions between etravirine and non-antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Non-nucleoside reverse transcriptase inhibitors: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Short Communication: High Effectiveness of Etravirine in Routine Clinical Practice in Treatment-Experienced HIV Type 1-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11209110-000000000-00000

Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network

21 January 2018

1 reference

12 December 2020

Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States

1 reference

12 December 2020

Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial

1 reference

12 December 2020

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients.

1 reference

12 December 2020

Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials

1 reference

12 December 2020

Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials

1 reference

12 December 2020

Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirine.

1 reference

12 December 2020

The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.

1 reference

12 December 2020

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen

1 reference

12 December 2020

Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women

1 reference

12 December 2020

Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection

1 reference

12 December 2020

Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection

1 reference

12 December 2020

10.2165/11209110-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1047568069

0 references

1 reference